-
1
-
-
34247508924
-
Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities
-
Massarweh S, Schiff R: Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 2007;13:1950-1954.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1950-1954
-
-
Massarweh, S.1
Schiff, R.2
-
2
-
-
11244296162
-
Mechanisms of tamoxi-fen resistance
-
Ring A, Dowsett M: Mechanisms of tamoxi-fen resistance. Endocr Relat Cancer 2004; 11: 643-658.
-
(2004)
Endocr Relat Cancer
, vol.11
, pp. 643-658
-
-
Ring, A.1
Dowsett, M.2
-
3
-
-
10644254128
-
Challenges in the endocrine management of breast cancer
-
Mouridsen HT, Rose C, Brodie AH, et al: Challenges in the endocrine management of breast cancer. Breast 2003;12:S2-S19.
-
(2003)
Breast
, vol.12
, pp. S2-S19
-
-
Mouridsen, H.T.1
Rose, C.2
Brodie, A.H.3
-
4
-
-
69249137029
-
Biological determinants of endocrine resistance in breast cancer
-
Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev 2009;9:631-643.
-
(2009)
Nat Rev
, vol.9
, pp. 631-643
-
-
Musgrove, E.A.1
Sutherland, R.L.2
-
5
-
-
0034466972
-
Estrogen receptor transcription and transacti-vation: Estrogen receptor alpha and estrogen receptor beta-regulation by selective estrogen receptor modulators and importance in breast cancer
-
Katzenellenbogen BS, Katzenellenbogen JA: Estrogen receptor transcription and transacti-vation: estrogen receptor alpha and estrogen receptor beta-regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2000; 2:335-344.
-
(2000)
Breast Cancer Res
, vol.2
, pp. 335-344
-
-
Katzenellenbogen, B.S.1
Katzenellenbogen, J.A.2
-
6
-
-
84982791018
-
Endocrine resistance in breast cancer
-
Dixon MJ: Endocrine resistance in breast cancer. New J Sci 2014; 2014:1-27.
-
(2014)
New J Sci
, vol.2014
, pp. 1-27
-
-
Dixon, M.J.1
-
7
-
-
39149113165
-
Development of the 21-gene assay and its application in clinical practice and clinical trials
-
Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26: 721-728.
-
(2008)
J Clin Oncol
, vol.26
, pp. 721-728
-
-
Sparano, J.A.1
Paik, S.2
-
8
-
-
33846869263
-
Resistance to endocrine therapy in breast cancer: Exploiting estrogen receptor/growth factor signaling crosstalk
-
Massarweh S, Schiff R: Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006; 13:S15-S24.
-
(2006)
Endocr Relat Cancer
, vol.13
, pp. S15-S24
-
-
Massarweh, S.1
Schiff, R.2
-
9
-
-
0032569831
-
Tamoxifen in the treatment of breast cancer
-
Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-1168.
-
(1998)
N Engl J Med
, vol.339
, pp. 1168-1609
-
-
Osborne, C.K.1
-
10
-
-
29144526402
-
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
-
Normanno N, Maio MD, Maio ED, et al: Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. En-docr Relat Cancer 2005; 12:721-747.
-
(2005)
En-docr Relat Cancer
, vol.12
, pp. 721-747
-
-
Normanno, N.1
Maio, M.D.2
Maio, E.D.3
-
11
-
-
0028861586
-
Use of tamoxifen for breast cancer: Twenty-eight years later
-
Jaiyesimi IA, Buzdar AU, Decker DA, et al: Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13:513-529.
-
(1995)
J Clin Oncol
, vol.13
, pp. 513-529
-
-
Jaiyesimi, I.A.1
Buzdar, A.U.2
Decker, D.A.3
-
12
-
-
79959344615
-
Estrogen receptor silencing induces epithelial to mes-enchymal transition in human breast cancer cells
-
Al Saleh S, Al Mulla F, Luqmani YA: Estrogen receptor silencing induces epithelial to mes-enchymal transition in human breast cancer cells. PLoS One 2011;6:1-10.
-
(2011)
PLoS One
, vol.6
, pp. 1-10
-
-
Al Saleh, S.1
Al Mulla, F.2
Luqmani, Y.A.3
-
13
-
-
84896259336
-
The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy
-
Austreid E, Lonning PE, Eikesdal HP: The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opin Pharmaco-ther 2014; 15:681-700.
-
(2014)
Expert Opin Pharmaco-ther
, vol.15
, pp. 681-700
-
-
Austreid, E.1
Lonning, P.E.2
Eikesdal, H.P.3
-
14
-
-
84872188345
-
Mechanisms of resistance to endocrine therapy in breast cancer: Focus in signaling pathways, miRNAs and genetically based resistance
-
Gracía-Becerra R, Santos N, Díaz L, et al: Mechanisms of resistance to endocrine therapy in breast cancer: focus in signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 2013; 14:108-145.
-
(2013)
Int J Mol Sci
, vol.14
, pp. 108-145
-
-
Gracía-Becerra, R.1
Santos, N.2
Díaz, L.3
-
15
-
-
0034665358
-
Al-losteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
-
MacGregor SJ, Liu H, Bentrem DJ, et al: Al-losteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 2000; 60:5097-5105.
-
(2000)
Cancer Res
, vol.60
, pp. 5097-5105
-
-
MacGregor, S.J.1
Liu, H.2
Bentrem, D.J.3
-
16
-
-
0033898141
-
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions
-
Fuqua SA, Wiltschke C, Zhang QX, et al: A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 2000; 60:4026-4029.
-
(2000)
Cancer Res
, vol.60
, pp. 4026-4029
-
-
Fuqua, S.A.1
Wiltschke, C.2
Zhang, Q.X.3
-
17
-
-
84898756681
-
Estrogen receptor mutations in breast cancer-new focus on an old target
-
Segal CV, Dowsett M: Estrogen receptor mutations in breast cancer-new focus on an old target. Clin Cancer Res 2014; 20:1724-1726.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 1724-1726
-
-
Segal, C.V.1
Dowsett, M.2
-
18
-
-
84884559238
-
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xe-nografts
-
Li S, Shen D, Shao J, et al: Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xe-nografts. Cell Rep 2013; 4:1116-1130.
-
(2013)
Cell Rep
, vol.4
, pp. 1116-1130
-
-
Li, S.1
Shen, D.2
Shao, J.3
-
19
-
-
84942293346
-
ESR1 mutations: A mechanism for acquired endocrine resistance in breast cancer
-
Jeselsohn R, Buchwalter G, De Angelis C, et al: ESR1 mutations: a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol 2015; 12:573-583.
-
(2015)
Nat Rev Clin Oncol
, vol.12
, pp. 573-583
-
-
Jeselsohn, R.1
Buchwalter, G.2
De Angelis, C.3
-
20
-
-
0035477320
-
Syn-ergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells
-
Yang X, Phillips DL, Ferguson AT, et al: Syn-ergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res 2001; 61:7025-7029.
-
(2001)
Cancer Res
, vol.61
, pp. 7025-7029
-
-
Yang, X.1
Phillips, D.L.2
Ferguson, A.T.3
-
21
-
-
0242659275
-
Multiple mechanisms of estrogen receptor gene repression contribute to ER-neg-ative breast cancer
-
Parl FF: Multiple mechanisms of estrogen receptor gene repression contribute to ER-neg-ative breast cancer. Pharmacogenomics J 2003; 3:251-253.
-
(2003)
Pharmacogenomics J
, vol.3
, pp. 251-253
-
-
Parl, F.F.1
-
22
-
-
85077951985
-
The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)
-
Marks PA: The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 2004; 3:534-535.
-
(2004)
Cell Cycle
, vol.3
, pp. 534-535
-
-
Marks, P.A.1
-
23
-
-
44749085668
-
ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor
-
Fan J, Yin WJ, Lu JS, et al: ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol 2008; 134:883-890.
-
(2008)
J Cancer Res Clin Oncol
, vol.134
, pp. 883-890
-
-
Fan, J.1
Yin, W.J.2
Lu, J.S.3
-
24
-
-
68949105725
-
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells
-
Zhou Q, Shaw PG, Davidson NE: Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res Treat 2009; 117:443-451.
-
(2009)
Breast Cancer Res Treat
, vol.117
, pp. 443-451
-
-
Zhou, Q.1
Shaw, P.G.2
Davidson, N.E.3
-
25
-
-
79952237710
-
Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole
-
Sabnis GJ, Goloubeva O, Chumsri S, et al: Functional activation of the estrogen recep-tor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 2011; 71:1893-1903.
-
(2011)
Cancer Res
, vol.71
, pp. 1893-1903
-
-
Sabnis, G.J.1
Goloubeva, O.2
Chumsri, S.3
-
26
-
-
84862656616
-
Scrip-taid effects on breast cancer cell lines
-
Giacinti L, Giacinti C, Gabellini C, et al: Scrip-taid effects on breast cancer cell lines. J Cell Physiol 2012; 227:3426-3433.
-
(2012)
J Cell Physiol
, vol.227
, pp. 3426-3433
-
-
Giacinti, L.1
Giacinti, C.2
Gabellini, C.3
-
27
-
-
0036488531
-
Endocrine-responsive breast cancer and strategies for combating resistance
-
Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-112.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 101-112
-
-
Ali, S.1
Coombes, R.C.2
-
28
-
-
69249137029
-
Biological determinants of endocrine resistance in breast cancer
-
Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9:631-643.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 631-643
-
-
Musgrove, E.A.1
Sutherland, R.L.2
-
29
-
-
63749086305
-
ErbB receptors and signaling pathways in cancer
-
Hynes NE, MacDonald G: ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21:1777-1784.
-
(2009)
Curr Opin Cell Biol
, vol.21
, pp. 1777-1784
-
-
Hynes, N.E.1
MacDonald, G.2
-
30
-
-
2942652871
-
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu crosstalk in ER/HER2-positive breast cancer
-
Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu crosstalk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96:926-935.
-
(2004)
J Natl Cancer Inst
, vol.96
, pp. 926-935
-
-
Shou, J.1
Massarweh, S.2
Osborne, C.K.3
-
31
-
-
77956251261
-
Simultaneous targeting of estrogen receptor and HER2 in breast cancer
-
Azim HA Jr, Piccart MJ: Simultaneous targeting of estrogen receptor and HER2 in breast cancer. Expert Rev Anticancer Ther 2010; 10: 1255-1263.
-
(2010)
Expert Rev Anticancer Ther
, vol.10
, pp. 1255-1263
-
-
Azim, H.A.1
Piccart, M.J.2
-
32
-
-
51049118140
-
An integrative genomic and pro-teomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
-
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al: An integrative genomic and pro-teomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68:6084-6091.
-
(2008)
Cancer Res
, vol.68
, pp. 6084-6091
-
-
Stemke-Hale, K.1
Gonzalez-Angulo, A.M.2
Lluch, A.3
-
33
-
-
0035971181
-
Phosphatidylinositol 3-kinase/AKT-medi-ated activation of estrogen receptor alpha: A new model for anti-estrogen resistance
-
Campbell RA, Bhat-Nakshatri P, Patel NM, et al: Phosphatidylinositol 3-kinase/AKT-medi-ated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276:9817-9824.
-
(2001)
J Biol Chem
, vol.276
, pp. 9817-9824
-
-
Campbell, R.A.1
Bhat-Nakshatri, P.2
Patel, N.M.3
-
34
-
-
0034794636
-
Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer
-
Dowsett M: Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001; 8: 191-195.
-
(2001)
Endocr Relat Cancer
, vol.8
, pp. 191-195
-
-
Dowsett, M.1
-
35
-
-
79952135852
-
The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells
-
Becker MA, Ibrahim YH, Cui X, et al: The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol 2011; 25:516-528.
-
(2011)
Mol Endocrinol
, vol.25
, pp. 516-528
-
-
Bonelli, M.A.1
Ibrahim, Y.H.2
Cui, X.3
-
36
-
-
77950793617
-
EGFR/HER2 inhibitor AEE788 increases ER-me-diated transcription in HER2/ER-positive breast cancer cells but functions synergisti-cally with endocrine therapy
-
Evans AH, Pancholi S, Farmer I, et al: EGFR/HER2 inhibitor AEE788 increases ER-me-diated transcription in HER2/ER-positive breast cancer cells but functions synergisti-cally with endocrine therapy. Br J Cancer 2010; 102:1235-1243.
-
(2010)
Br J Cancer
, vol.102
, pp. 1235-1243
-
-
Evans, A.H.1
Pancholi, S.2
Farmer, I.3
-
37
-
-
84861823850
-
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
-
Cavazzoni A, Bonelli MA, Fumarola C, et al: Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett 2012; 323:77-87.
-
(2012)
Cancer Lett
, vol.323
, pp. 77-87
-
-
Cavazzoni, A.1
Bonelli, M.A.2
Fumarola, C.3
-
38
-
-
84880264411
-
Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor
-
Vilquin P, Villedieu M, Grisard E, et al: Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer 2013; 133:1589-1602.
-
(2013)
Int J Cancer
, vol.133
, pp. 1589-1602
-
-
Vilquin, P.1
Villedieu, M.2
Grisard, E.3
-
39
-
-
84876204394
-
Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer
-
Magnani L, Stoeck A, Zhang X, et al: Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci USA 2013; 110:E1490-E1499.
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. E1490-E1499
-
-
Magnani, L.1
Stoeck, A.2
Zhang, X.3
-
40
-
-
84866145981
-
The interaction between ER and NFκB in resistance to endocrine therapy
-
Sas L, Lardon F, Vermeulen PB, et al: The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Res 2012; 14:212-216.
-
(2012)
Breast Cancer Res
, vol.14
, pp. 212-216
-
-
Sas, L.1
Lardon, F.2
Vermeulen, P.B.3
-
41
-
-
84907873145
-
Endocrine resistance in breast cancer
-
Zheng LH, Zhao YH, Feng HL, et al: Endocrine resistance in breast cancer. Climacteric 2014; 17:522-528.
-
(2014)
Climacteric
, vol.17
, pp. 522-528
-
-
Zheng, L.H.1
Zhao, Y.H.2
Feng, H.L.3
-
42
-
-
34247242607
-
Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer
-
Zhou Y, Yau C, Gray JW, et al: Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007; 7:59.
-
(2007)
BMC Cancer
, vol.7
, pp. 59
-
-
Zhou, Y.1
Yau, C.2
Gray, J.W.3
-
43
-
-
3442901974
-
NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen
-
deGraffenried LA, Chandrasekar B, Fried-richs WE, et al: NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 2006; 15: 885-890.
-
(2006)
Ann Oncol
, vol.15
, pp. 885-890
-
-
DeGraffenried, L.A.1
Chandrasekar, B.2
Fried-Richs, W.E.3
-
45
-
-
23244451640
-
Mac-rophages induce invasiveness of epithelial cancer cells via NF-κB and JNK
-
Hagemann T, Wilson J, Kulbe H, et al: Mac-rophages induce invasiveness of epithelial cancer cells via NF-κB and JNK. J Immunol 2005; 175:1197-1205.
-
(2005)
J Immunol
, vol.175
, pp. 1197-1205
-
-
Hagemann, T.1
Wilson, J.2
Kulbe, H.3
-
46
-
-
66349123393
-
Tamoxifen metabolism and its effect on endocrine treatment of breast cancer
-
Briest S, Stearns V: Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin Adv Hematol Oncol 2009; 7:185-192.
-
(2009)
Clin Adv Hematol Oncol
, vol.7
, pp. 185-192
-
-
Briest, S.1
Stearns, V.2
-
47
-
-
79951891762
-
Endoxifen, the active metabolite to tamoxifen, is a substrate of efflux transporter P-glycoprotein (multi-drug resistance 1)
-
Teft WA, Mansell SE, Kim RB: Endoxifen, the active metabolite to tamoxifen, is a substrate of efflux transporter P-glycoprotein (multi-drug resistance 1). Drug Metab Dispos 2011; 39:558-562.
-
(2011)
Drug Metab Dispos
, vol.39
, pp. 558-562
-
-
Teft, W.A.1
Mansell, S.E.2
Kim, R.B.3
-
48
-
-
11244296162
-
Mechanisms of tamoxi-fen resistance
-
Ring A, Dowsett M: Mechanisms of tamoxi-fen resistance. Endocr Relat Cancer 2004; 11: 643-658.
-
(2004)
Endocr Relat Cancer
, vol.11
, pp. 643-658
-
-
Ring, A.1
Dowsett, M.2
-
49
-
-
77955661193
-
Orally administered endoxifen is a new therapeutic agent for breast cancer
-
Ahmad A, Ali SM, Ahmad MU, et al: Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res Treat 2010; 122:579-584.
-
(2010)
Breast Cancer Res Treat
, vol.122
, pp. 579-584
-
-
Ahmad, A.1
Ali, S.M.2
Ahmad, M.U.3
-
50
-
-
0034466973
-
Estrogen receptor transcription and transactivation: Basic aspects of estrogen action
-
Nilsson S, Gustafsson J-A: Estrogen receptor transcription and transactivation: Basic aspects of estrogen action. Breast Cancer Res 2000; 2:360-366.
-
(2000)
Breast Cancer Res
, vol.2
, pp. 360-366
-
-
Nilsson, S.1
Gustafsson, J.-A.2
-
51
-
-
0034868904
-
ERβ inhibits proliferation and invasion of breast cancer cells
-
Lazennec G, Bresson D, Lucas A, et al: ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001; 142:4120-4130.
-
(2001)
Endocrinology
, vol.142
, pp. 4120-4130
-
-
Lazennec, G.1
Bresson, D.2
Lucas, A.3
-
52
-
-
9344264630
-
Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer
-
Hopp TA, Weiss HL, Parra IS, et al: Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004; 10:7490-7499.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 7490-7499
-
-
Hopp, T.A.1
Weiss, H.L.2
Parra, I.S.3
-
53
-
-
0037025323
-
Opposing action of estrogen receptor α and β on cyclin D1 gene expression
-
Liu M-M, Albanese C, Anderson CM, et al: Opposing action of estrogen receptor α and β on cyclin D1 gene expression. J Biol Chem 2002; 277:24353-24360.
-
(2002)
J Biol Chem
, vol.277
, pp. 24353-24360
-
-
Liu, M.-M.1
Albanese, C.2
Anderson, C.M.3
-
54
-
-
0030801841
-
Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP-1 sites
-
Paech KM, Webb P, Kuiper GG, et al: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP-1 sites. Science 1997; 277:1508-1510.
-
(1997)
Science
, vol.277
, pp. 1508-1510
-
-
Paech, K.M.1
Webb, P.2
Kuiper, G.G.3
-
55
-
-
0033524443
-
Segregation of steroid receptor coactivator-1 from steroid receptors in mammary epithelium
-
Shim W-S, DiRenzo J, DeCaprio JA, et al: Segregation of steroid receptor coactivator-1 from steroid receptors in mammary epithelium. Proc Natl Acad Sci USA 1999;96:208-213.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 208-213
-
-
Shim, W.-S.1
DiRenzo, J.2
DeCaprio, J.A.3
-
56
-
-
0032230350
-
Estrogen receptor activation function 1 works by binding p160 co-activator proteins
-
Webb P, Nguyen P, Shinsako J, et al: Estrogen receptor activation function 1 works by binding p160 co-activator proteins. Mol Endocri-nol 1998; 12:1605-1618.
-
(1998)
Mol Endocri-nol
, vol.12
, pp. 1605-1618
-
-
Webb, P.1
Nguyen, P.2
Shinsako, J.3
-
57
-
-
11744282298
-
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
-
Lavinsky RM, Jepsen K, Heinzel T, et al: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 1998;95: 2920-2925.
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 2920-2925
-
-
Lavinsky, R.M.1
Jepsen, K.2
Heinzel, T.3
-
58
-
-
84887613510
-
Tumor and its microenvironment: A synergistic interplay
-
Catalano V, Turdo A, Franco SD, et al: Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 2013; 23:522-532.
-
(2013)
Semin Cancer Biol
, vol.23
, pp. 522-532
-
-
Catalano, V.1
Turdo, A.2
Franco, S.D.3
-
59
-
-
5044238876
-
Integrin signaling during tumor progression
-
Guo W, Giancotti FG: Integrin signaling during tumor progression. Nat Rev 2004;5:816-826.
-
(2004)
Nat Rev
, vol.5
, pp. 816-826
-
-
Guo, W.1
Giancotti, F.G.2
-
61
-
-
33746764457
-
4 Integrin amplifies ErbB2 signaling to promote mammary tumorigenesis
-
4 Integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006; 126:489-502.
-
(2006)
Cell
, vol.126
, pp. 489-502
-
-
Guo, W.1
Pylayeva, Y.2
Pepe, A.3
-
62
-
-
0029564954
-
Heat shock transcription factors: Structure and regulation
-
Wu C: Heat shock transcription factors: structure and regulation. Ann Rev Cell Dev Biol 1995;11:441-469.
-
(1995)
Ann Rev Cell Dev Biol
, vol.11
, pp. 441-469
-
-
Wu, C.1
-
63
-
-
17844394391
-
Mitogen-activated protein kinase activation in UV-induced signal trans-duction
-
Bode AM, Dong Z: Mitogen-activated protein kinase activation in UV-induced signal trans-duction. Sci STKE 2003;167:RE2.
-
(2003)
Sci STKE
, vol.167
, pp. RE2
-
-
Bode, A.M.1
Dong, Z.2
-
64
-
-
0141509074
-
Cancer: The rules of attraction
-
Neckers L, Lee YS: Cancer: the rules of attraction. Nature 2003;425:357-359.
-
(2003)
Nature
, vol.425
, pp. 357-359
-
-
Neckers, L.1
Lee, Y.S.2
-
65
-
-
17844398046
-
Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
-
Gutierrez MC, Detre S, Johnston S, et al: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005; 23:2469-2476.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2469-2476
-
-
Gutierrez, M.C.1
Detre, S.2
Johnston, S.3
-
66
-
-
74949101730
-
Challenges in defining predictive markers for response to endocrine therapy in breast cancer
-
Larionov AA, Miller WR: Challenges in defining predictive markers for response to endocrine therapy in breast cancer. Future Oncol 2009; 5:1415-1428.
-
(2009)
Future Oncol
, vol.5
, pp. 1415-1428
-
-
Larionov, A.A.1
Miller, W.R.2
-
68
-
-
63049137792
-
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole
-
Miller WR, Larionov A, Renshaw L, et al: Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 2009; 27: 1382-1387.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1382-1387
-
-
Miller, W.R.1
Larionov, A.2
Renshaw, L.3
-
69
-
-
1642386264
-
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model
-
Long BJ, Jelovac D, Handratta V, et al: Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 2004; 96:456-465.
-
(2004)
J Natl Cancer Inst
, vol.96
, pp. 456-465
-
-
Long, B.J.1
Jelovac, D.2
Handratta, V.3
-
70
-
-
20444448539
-
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model
-
Jelovac D, Macedo L, Goloubeva OG, et al: Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005; 65:5439-5444.
-
(2005)
Cancer Res
, vol.65
, pp. 5439-5444
-
-
Jelovac, D.1
MacEdo, L.2
Goloubeva, O.G.3
-
71
-
-
84867891436
-
Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?
-
Fedele P, Calvani N, Marino A, et al: Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Crit Rev Oncol Hematol 2012; 84:243-251.
-
(2012)
Crit Rev Oncol Hematol
, vol.84
, pp. 243-251
-
-
Fedele, P.1
Calvani, N.2
Marino, A.3
-
72
-
-
84861823850
-
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
-
Cavazzoni A, Bonelli MA, Fumarola C, et al: Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett 2012; 323:77-87.
-
(2012)
Cancer Lett
, vol.323
, pp. 77-87
-
-
Cavazzoni, A.1
Bonelli, M.A.2
Fumarola, C.3
-
73
-
-
84864107018
-
Everolimus: Targeted therapy on the horizon for the treatment of breast cancer
-
Barnett CM: Everolimus: targeted therapy on the horizon for the treatment of breast cancer. Pharmacotherapy 2012; 32:383-396.
-
(2012)
Pharmacotherapy
, vol.32
, pp. 383-396
-
-
Barnett, C.M.1
-
74
-
-
84893646332
-
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure
-
Massarweh S, Romond E, Black EP, et al: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Res Treat 2014; 143:325-332.
-
(2014)
Breast Cancer Res Treat
, vol.143
, pp. 325-332
-
-
Massarweh, S.1
Romond, E.2
Black, E.P.3
-
75
-
-
0020358296
-
Epithelial suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells
-
Greenburg G, Hay ED: Epithelial suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 1982; 95:335-339.
-
(1982)
J Cell Biol
, vol.95
, pp. 335-339
-
-
Greenburg, G.1
Hay, E.D.2
-
76
-
-
34447272058
-
Mechanisms of metastasis: Epithelial-mesenchymal transition and contribution of tumor microenvironment
-
Tse JC, Kalluri R: Mechanisms of metastasis: epithelial-mesenchymal transition and contribution of tumor microenvironment. J Cell Biol 2007; 101:816-829.
-
(2007)
J Cell Biol
, vol.101
, pp. 816-829
-
-
Tse, J.C.1
Kalluri, R.2
-
77
-
-
84873050284
-
Regulatory network defining EMT during cancer initiation and progression
-
De Craene B, Berx G: Regulatory network defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13:97-110.
-
(2013)
Nat Rev Cancer
, vol.13
, pp. 97-110
-
-
De Craene, B.1
Berx, G.2
-
78
-
-
0033784843
-
The transcription factor Snail controls epithe-lial-mesenchymal transitions by repressing E-cadherin expression
-
Cano A, Perez-Moreno MA, Rodrigo I, et al: The transcription factor Snail controls epithe-lial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83.
-
(2000)
Nat Cell Biol
, vol.2
, pp. 76-83
-
-
Cano, A.1
Perez-Moreno, M.A.2
Rodrigo, I.3
-
79
-
-
33750358078
-
Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition
-
Moreno-Bueno G, Cubillo E, Sarrio D, et al: Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 2006; 66: 9543-9556.
-
(2006)
Cancer Res
, vol.66
, pp. 9543-9556
-
-
Moreno-Bueno, G.1
Cubillo, E.2
Sarrio, D.3
-
80
-
-
33244463813
-
Complex networks orchestrate epithelial-mesenchymal transition
-
Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transition. Mol Cell Biol 2006; 7:131-142.
-
(2006)
Mol Cell Biol
, vol.7
, pp. 131-142
-
-
Thiery, J.P.1
Sleeman, J.P.2
-
81
-
-
64549090709
-
Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition
-
Sivakumar R, Koga H, Selvendiran K, et al: Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition. Intl J Oncol 2009; 34:392-338.
-
(2009)
Intl J Oncol
, vol.34
, pp. 338-392
-
-
Sivakumar, R.1
Koga, H.2
Selvendiran, K.3
-
82
-
-
65349116534
-
Trans-lational activation of snail1 and other devel-opmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition
-
Evdokimova V, Tognon C, Ng T, et al: Trans-lational activation of snail1 and other devel-opmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15:402-415.
-
(2009)
Cancer Cell
, vol.15
, pp. 402-415
-
-
Evdokimova, V.1
Tognon, C.2
Ng, T.3
-
83
-
-
12144266241
-
Gly-cogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: Implications for the epithelial-mesenchymal transition
-
Bachelder RE, Yoon SO, Franci C, et al: Gly-cogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 2005; 168:29-33.
-
(2005)
J Cell Biol
, vol.168
, pp. 29-33
-
-
Bachelder, R.E.1
Yoon, S.O.2
Franci, C.3
-
84
-
-
77952952860
-
Role of CK1 in GSK3β-mediated phosphorylation and degradation of snail
-
Xu Y, Lee SH, Kim HS, et al: Role of CK1 in GSK3β-mediated phosphorylation and degradation of snail. Oncogene 2010; 29:3124-3133.
-
(2010)
Oncogene
, vol.29
, pp. 3124-3133
-
-
Xu, Y.1
Lee, S.H.2
Kim, H.S.3
-
85
-
-
77950346282
-
Immunity, inflammation, and cancer
-
Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010; 140:883-899.
-
(2010)
Cell
, vol.140
, pp. 883-899
-
-
Grivennikov, S.I.1
Greten, F.R.2
Karin, M.3
-
86
-
-
0033578314
-
Mechanism for elimination of a tumor suppressor: Aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma
-
Ge K, DuHadaway J, Du W, et al: Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci USA 1999; 96:9689-9694.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 9689-9694
-
-
Ge, K.1
DuHadaway, J.2
Du, W.3
-
87
-
-
84941243013
-
Distinct EMT programs control normal mammary stem cells and tumour-initiating cells
-
Ye X, Tam WL, Shibue T, et al: Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 2015; 525:256-260.
-
(2015)
Nature
, vol.525
, pp. 256-260
-
-
Ye, X.1
Tam, W.L.2
Shibue, T.3
-
88
-
-
77949423072
-
ERα signaling through slug regulates E-cadherin and EMT
-
Ye Y, Xiao Y, Wang W, et al: ERα signaling through slug regulates E-cadherin and EMT. Oncogene 2010; 29:1451-1462.
-
(2010)
Oncogene
, vol.29
, pp. 1451-1462
-
-
Ye, Y.1
Xiao, Y.2
Wang, W.3
-
89
-
-
79951681780
-
Drug resistant MCF-7 cells exhibit epithelial-mes-enchymal transition gene expression pattern
-
Iseri OD, Kars MD, Arpaci F, et al: Drug resistant MCF-7 cells exhibit epithelial-mes-enchymal transition gene expression pattern. Biomed Pharmacother 2011; 65:40-45.
-
(2011)
Biomed Pharmacother
, vol.65
, pp. 40-45
-
-
Iseri, O.D.1
Kars, M.D.2
Arpaci, F.3
-
90
-
-
0035496541
-
The role of c-ErbB-2/HER2/neu in breast cancer progression and metastasis
-
Eccles SA: The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001; 6: 393-406.
-
(2001)
J Mammary Gland Biol Neoplasia
, vol.6
, pp. 393-406
-
-
Eccles, S.A.1
-
91
-
-
0026443229
-
Mechanisms of c-erbB2-2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products
-
Yu D, Hamada J, Zhand H, et al: Mechanisms of c-erbB2-2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 1992; 7:2263-2270.
-
(1992)
Oncogene
, vol.7
, pp. 2263-2270
-
-
Yu, D.1
Hamada, J.2
Zhand, H.3
-
92
-
-
84862820130
-
Epithelial-mes-enchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype
-
Jeong H, Ryu Y-J, An J, et al: Epithelial-mes-enchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathol 2012; 60: E87-E95.
-
(2012)
Histopathol
, vol.60
, pp. E87-E95
-
-
Jeong, H.1
Ryu, Y.-J.2
An, J.3
-
93
-
-
60749137227
-
Modification of gene expression induced by siRNA targeting of estrogen receptor in MCF-7 human breast cancer cells
-
Luqmani YA, Al Azmi A, Al Bader M, et al: Modification of gene expression induced by siRNA targeting of estrogen receptor in MCF-7 human breast cancer cells. Int J Oncol 2009; 34:231-242.
-
(2009)
Int J Oncol
, vol.34
, pp. 231-242
-
-
Luqmani, Y.A.1
Al Azmi, A.2
Al Bader, M.3
-
94
-
-
36849002930
-
The transcription factor snail mediates epithelial to mesenchymal transition by repression of estrogen receptor-α
-
Dhasarathy A, Kajita M, Wade PA: The transcription factor snail mediates epithelial to mesenchymal transition by repression of estrogen receptor-α. Mol Endocrinol 2007; 21: 2907-2918.
-
(2007)
Mol Endocrinol
, vol.21
, pp. 2907-2918
-
-
Dhasarathy, A.1
Kajita, M.2
Wade, P.A.3
-
95
-
-
80052403945
-
The EMT regulator slug and lung carcinogenesis
-
Shih J-Y, Yang P-C: The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011; 32:1299-1304.
-
(2011)
Carcinogenesis
, vol.32
, pp. 1299-1304
-
-
Shih, J.-Y.1
Yang, P.-C.2
-
96
-
-
84982791018
-
Endocrine resistance in breast cancer
-
Dixon MJ: Endocrine resistance in breast cancer. New J Sci 2014; 2014:1-27.
-
(2014)
New J Sci
, vol.2014
, pp. 1-27
-
-
Dixon, M.J.1
-
97
-
-
79954999152
-
Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition
-
Al Saleh S, Sharaf LH, Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition. Int J Oncol 2011a;38: 1197-1217.
-
(2011)
Int J Oncol
, vol.38
, pp. 1197-1217
-
-
Al Saleh, S.1
Sharaf, L.H.2
Luqmani, Y.A.3
-
98
-
-
84875505291
-
The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer
-
Loh YN, Hedditch EL, Baker LA, et al: The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer 2013; 13: 174-181.
-
(2013)
BMC Cancer
, vol.13
, pp. 174-181
-
-
Loh, Y.N.1
Hedditch, E.L.2
Baker, L.A.3
-
99
-
-
84896489562
-
Eribu-lin mesilate suppresses experimental metastasis of breast cancer cells by reversing phe-notype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states
-
Yoshida T, Ozawa Y, Kimura T, et al: Eribu-lin mesilate suppresses experimental metastasis of breast cancer cells by reversing phe-notype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 2014; 110:1497-1505.
-
(2014)
Br J Cancer
, vol.110
, pp. 1497-1505
-
-
Yoshida, T.1
Ozawa, Y.2
Kimura, T.3
-
100
-
-
84910639102
-
Centchro-man suppresses breast cancer metastasis by reversing epithelialmesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling
-
Khan S, Shukla S, Sinha S, et al: Centchro-man suppresses breast cancer metastasis by reversing epithelialmesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling. Intl J Biochem Cell Biol 2014; 58:1-16.
-
(2014)
Intl J Biochem Cell Biol
, vol.58
, pp. 1-16
-
-
Khan, S.1
Shukla, S.2
Sinha, S.3
-
101
-
-
77953765387
-
Doxorubicin in combination with a small TGFβ inhibitor: A potential novel therapy for metastatic breast cancer in mouse models
-
Bandyopadhyay A, Wang L, Agyin J, et al: Doxorubicin in combination with a small TGFβ inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010; 5:1-13.
-
(2010)
PLoS One
, vol.5
, pp. 1-13
-
-
Bandyopadhyay, A.1
Wang, L.2
Agyin, J.3
-
102
-
-
84860386584
-
MiRNAs and estrogen action
-
Klinge CM: miRNAs and estrogen action. Trends Endocrinol Metab 2012; 23:223-233.
-
(2012)
Trends Endocrinol Metab
, vol.23
, pp. 223-233
-
-
Klinge, C.M.1
-
103
-
-
72949098057
-
Therapeutic microRNA strategies in human cancer
-
Li C, Feng Y, Coukos G, et al: Therapeutic microRNA strategies in human cancer. AAPS J 2009; 11:747-757.
-
(2009)
AAPS J
, vol.11
, pp. 747-757
-
-
Li, C.1
Feng, Y.2
Coukos, G.3
-
104
-
-
80054090363
-
Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells
-
Manavalan TT, Teng Y, Appana SN, et al: Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Lett 2011; 313:26-43.
-
(2011)
Cancer Lett
, vol.313
, pp. 26-43
-
-
Manavalan, T.T.1
Teng, Y.2
Appana, S.N.3
-
106
-
-
77956501846
-
Modulation of K-Ras-dependent lung tu-morigenesis by microRNA-21
-
Hatley ME, Patrick DM, Garcia MR, et al: Modulation of K-Ras-dependent lung tu-morigenesis by microRNA-21. Cancer Cell 2010; 18:282-293.
-
(2010)
Cancer Cell
, vol.18
, pp. 282-293
-
-
Hatley, M.E.1
Patrick, D.M.2
Garcia, M.R.3
-
107
-
-
77954030587
-
Genetic variation in microRNA networks: The implications for cancer research
-
Ryan BM, Robles AI, Harris CC: Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10:389-402.
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 389-402
-
-
Ryan, B.M.1
Robles, A.I.2
Harris, C.C.3
-
108
-
-
77957091969
-
Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis
-
Kosaka N, Iguchi H, Ochiya T: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. J Cancer Sci 2010; 101:2087-2092.
-
(2010)
J Cancer Sci
, vol.101
, pp. 2087-2092
-
-
Kosaka, N.1
Iguchi, H.2
Ochiya, T.3
-
110
-
-
84863906869
-
MicroRNAs as therapeutic targets and their potential applications in cancer therapy
-
Cho WC: MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets 2012; 16: 747-759.
-
(2012)
Expert Opin Ther Targets
, vol.16
, pp. 747-759
-
-
Cho, W.C.1
-
112
-
-
84862109179
-
Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: A DBCG study
-
Lyng MB, Laenkholm AV, Sokilde R, et al: Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study. PLoS One 2012; 7:e36170.
-
(2012)
PLoS One
, vol.7
, pp. e36170
-
-
Lyng, M.B.1
Laenkholm, A.V.2
Sokilde, R.3
-
114
-
-
77649275464
-
MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
-
Ma L, Young J, Prabhala H, et al: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12:247-256.
-
(2010)
Nat Cell Biol
, vol.12
, pp. 247-256
-
-
Ma, L.1
Young, J.2
Prabhala, H.3
-
115
-
-
77952921840
-
Mi-croRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer
-
Di Leva G, Gasparini P, Piovan C, et al: Mi-croRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 2010; 102:706-721.
-
(2010)
J Natl Cancer Inst
, vol.102
, pp. 706-721
-
-
Di Leva, G.1
Gasparini, P.2
Piovan, C.3
-
116
-
-
57649174634
-
MicroR-NA-221/222 negatively regulates estrogen receptor alpha and is associated with tamox-ifen resistance in breast cancer
-
Zhao JJ, Lin J, Yang H, et al: MicroR-NA-221/222 negatively regulates estrogen receptor alpha and is associated with tamox-ifen resistance in breast cancer. J Biol Chem 2008; 283:31079-31086.
-
(2008)
J Biol Chem
, vol.283
, pp. 31079-31086
-
-
Zhao, J.J.1
Lin, J.2
Yang, H.3
-
117
-
-
79952281614
-
Micro-RNA-221/222 confers breast cancer fulves-trant resistance by regulating multiple signaling pathways
-
Rao X, di Leva G, Li M, et al: Micro-RNA-221/222 confers breast cancer fulves-trant resistance by regulating multiple signaling pathways. Oncogene 2011; 30:1082-1097.
-
(2011)
Oncogene
, vol.30
, pp. 1082-1097
-
-
Rao, X.1
Di Leva, G.2
Li, M.3
-
118
-
-
84930001098
-
Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells
-
Wei Y, Lai X, Yu S, et al: Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat 2014; 47:423-231.
-
(2014)
Breast Cancer Res Treat
, vol.47
, pp. 423-431
-
-
Wei, Y.1
Lai, X.2
Yu, S.3
-
119
-
-
67650135755
-
MiR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA
-
Pandey DP, Picard D: miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 2009; 29:3783-3790.
-
(2009)
Mol Cell Biol
, vol.29
, pp. 3783-3790
-
-
Pandey, D.P.1
Picard, D.2
-
120
-
-
38049115129
-
Endogenous human microRNAs that suppress breast cancer metastasis
-
Tavazoie SF, Alarcon C, Oskarsson T, et al: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451:147-152.
-
(2008)
Nature
, vol.451
, pp. 147-152
-
-
Tavazoie, S.F.1
Alarcon, C.2
Oskarsson, T.3
-
121
-
-
84874787674
-
MiR-124 targets Slug to regulate epithelial-mes-enchymal transition and metastasis of breast cancer
-
Liang YJ, Wang QY, Zhou CX, et al: MiR-124 targets Slug to regulate epithelial-mes-enchymal transition and metastasis of breast cancer. Carcinogenesis 2013; 34:713-722.
-
(2013)
Carcinogenesis
, vol.34
, pp. 713-722
-
-
Liang, Y.J.1
Wang, Q.Y.2
Zhou, C.X.3
-
122
-
-
78650179541
-
Involvement of NF-kappaB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells
-
Li QQ, Chen ZQ, Cao XX, et al: Involvement of NF-kappaB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ 2011; 18:16-26.
-
(2011)
Cell Death Differ
, vol.18
, pp. 16-26
-
-
Li, Q.Q.1
Chen, Z.Q.2
Cao, X.X.3
-
123
-
-
84889970352
-
Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer
-
Li L, Luo J, Wang B, et al: Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. Mol Cancer 2013; 12:1476-4598.
-
(2013)
Mol Cancer
, vol.12
, pp. 1476-4598
-
-
Li, L.1
Luo, J.2
Wang, B.3
-
124
-
-
84871067207
-
MiR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-meta-static genes in vitro
-
Lv XB, Jiao Y, Qing Y, et al: miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-meta-static genes in vitro. Chin J Cancer 2011; 30: 821-830.
-
(2011)
Chin J Cancer
, vol.30
, pp. 821-830
-
-
Lv, X.B.1
Jiao, Y.2
Qing, Y.3
-
125
-
-
84921341682
-
Micro-RNA-145 inhibits lung cancer metastasis
-
Ling DJ, Chen ZS, Zhang YD, et al: Micro-RNA-145 inhibits lung cancer metastasis. Mol Med Rep 2015; 11:3108-3114.
-
(2015)
Mol Med Rep
, vol.11
, pp. 3108-3114
-
-
Ling, D.J.1
Chen, Z.S.2
Zhang, Y.D.3
-
126
-
-
67349149082
-
MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells
-
Xu N, Papaginnakopoulos T, Pan G, et al: MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009; 137:647-658.
-
(2009)
Cell
, vol.137
, pp. 647-658
-
-
Xu, N.1
Papaginnakopoulos, T.2
Pan, G.3
-
127
-
-
84908059702
-
MicroR-NA-145: A potent tumor suppressor that regulates multiple cellular pathways
-
Cui S-Y, Wang R, Chen L-B: MicroR-NA-145: a potent tumor suppressor that regulates multiple cellular pathways. J Cell Mol Med 2014; 18:1913-1926.
-
(2014)
J Cell Mol Med
, vol.18
, pp. 1913-1926
-
-
Cui, S.-Y.1
Wang, R.2
Chen, L.-B.3
-
128
-
-
67650538055
-
Up-regu-lation of miR-21 by HER2/neu signaling promotes cell invasion
-
Huang TH, Wu F, Loeb GB, et al: Up-regu-lation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem 2009; 284:18515-18524.
-
(2009)
J Biol Chem
, vol.284
, pp. 18515-18524
-
-
Huang, T.H.1
Wu, F.2
Loeb, G.B.3
-
129
-
-
34547791273
-
Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation
-
le Sage C, Nagel R, Egan DA, et al: Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26:3699-3708.
-
(2007)
EMBO J
, vol.26
, pp. 3699-3708
-
-
Le Sage, C.1
Nagel, R.2
Egan, D.A.3
-
130
-
-
84887840885
-
MIR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion
-
Falkenberg N, Anastosov N, Rappl K, et al: MIR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer 2013; 109: 2714-2723.
-
(2013)
Br J Cancer
, vol.109
, pp. 2714-2723
-
-
Falkenberg, N.1
Anastosov, N.2
Rappl, K.3
-
131
-
-
84928585732
-
MicroRNA-124 inhibits cellular proliferation and invasion by targeting Ets-1 in breast cancer
-
Li W, Zang W, Liu P, et al: MicroRNA-124 inhibits cellular proliferation and invasion by targeting Ets-1 in breast cancer. Tumour Biol 2014; 35:10897-10904.
-
(2014)
Tumour Biol
, vol.35
, pp. 10897-10904
-
-
Li, W.1
Zang, W.2
Liu, P.3
-
132
-
-
0036010596
-
Fas-cins and their roles in cell structure and function
-
Kureishy N, Sapountzi V, Prag S, et al: Fas-cins and their roles in cell structure and function. Bioessays 2002; 24:350-361.
-
(2002)
Bioessays
, vol.24
, pp. 350-361
-
-
Kureishy, N.1
Sapountzi, V.2
Prag, S.3
-
133
-
-
84860389407
-
Breast cancer cells migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase
-
McSherry EA, Brennan K, Hudson L, et al: Breast cancer cells migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase. Breast Cancer Res 2011; 13:1-14.
-
(2011)
Breast Cancer Res
, vol.13
, pp. 1-14
-
-
McSherry, E.A.1
Brennan, K.2
Hudson, L.3
-
134
-
-
75149124701
-
MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1
-
Sachdeva M, Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70:378-387.
-
(2010)
Cancer Res
, vol.70
, pp. 378-387
-
-
Sachdeva, M.1
Mo, Y.Y.2
-
135
-
-
51349103144
-
Four miRi NAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
-
Foekens JA, Sieuwerts AM, Smid M, et al: Four miRi NAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 2008; 105:13021-13026.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 13021-13026
-
-
Foekens, J.A.1
Sieuwerts, A.M.2
Smid, M.3
-
136
-
-
40949137731
-
Hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer
-
Camps C, Buffa FM, Colella S, et al: hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008; 14:1340-1348.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 1340-1348
-
-
Camps, C.1
Buffa, F.M.2
Colella, S.3
-
137
-
-
79959637929
-
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer
-
Rothe F, Ignatiadis M, Chaboteaux C, et al: Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 2011; 6:e20980.
-
(2011)
PLoS One
, vol.6
, pp. e20980
-
-
Rothe, F.1
Ignatiadis, M.2
Chaboteaux, C.3
-
138
-
-
80052223077
-
Mi-croRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer
-
Buffa FM, Camps C, Winchester L, et al: mi-croRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011; 71:5635-5645.
-
(2011)
Cancer Res
, vol.71
, pp. 5635-5645
-
-
Buffa, F.M.1
Camps, C.2
Winchester, L.3
-
139
-
-
79851479816
-
MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer
-
Radojicic J, Zaravinos A, Vrekoussis T, et al: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10:507-517.
-
(2011)
Cell Cycle
, vol.10
, pp. 507-517
-
-
Radojicic, J.1
Zaravinos, A.2
Vrekoussis, T.3
-
140
-
-
69049120925
-
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1
-
Qian B, Katsaros D, Lu L, et al: High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 2009; 117:131-140.
-
(2009)
Breast Cancer Res Treat
, vol.117
, pp. 131-140
-
-
Qian, B.1
Katsaros, D.2
Lu, L.3
-
141
-
-
79956313718
-
Up-regulation of miR-21 mediates resistance to trastuzum-ab therapy for breast cancer
-
Gong C, Yao Y, Wang Y, et al: Up-regulation of miR-21 mediates resistance to trastuzum-ab therapy for breast cancer. J Biol Chem 2011; 286:19127-19137.
-
(2011)
J Biol Chem
, vol.286
, pp. 19127-19137
-
-
Gong, C.1
Yao, Y.2
Wang, Y.3
-
142
-
-
66449095667
-
A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis
-
Valastyan S, Reinhardt F, Benaich N, et al: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137:1032-1046.
-
(2009)
Cell
, vol.137
, pp. 1032-1046
-
-
Valastyan, S.1
Reinhardt, F.2
Benaich, N.3
-
143
-
-
66449136951
-
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model
-
Kota J, Chivukula RR, O'Donnell KA, et al: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137:1005-1017.
-
(2009)
Cell
, vol.137
, pp. 1005-1017
-
-
Kota, J.1
Chivukula, R.R.2
O'Donnell, K.A.3
-
144
-
-
28444469246
-
Silencing of microRNAs in vivo with 'an-tagomirs'
-
Krutzfeldt J, Rajewsky N, Braich R, et al: Silencing of microRNAs in vivo with 'an-tagomirs'. Nature 2005; 438:685-689.
-
(2005)
Nature
, vol.438
, pp. 685-689
-
-
Krutzfeldt, J.1
Rajewsky, N.2
Braich, R.3
-
145
-
-
40249106014
-
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver
-
Elmen J, Lindow M, Silahtaroglu A, et al: Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008; 36:1153-1162.
-
(2008)
Nucleic Acids Res
, vol.36
, pp. 1153-1162
-
-
Elmen, J.1
Lindow, M.2
Silahtaroglu, A.3
-
146
-
-
37349113774
-
Inhibition of microRNA with an-tisense oligonucleotides
-
Esau CC: Inhibition of microRNA with an-tisense oligonucleotides. Methods 2008; 44: 55-60.
-
(2008)
Methods
, vol.44
, pp. 55-60
-
-
Esau, C.C.1
-
147
-
-
34247495591
-
MiR-21-mediated tumor growth
-
Si ML, Zhu S, Wu H, et al: miR-21-mediated tumor growth. Oncogene 2007; 26:2799-2803.
-
(2007)
Oncogene
, vol.26
, pp. 2799-2803
-
-
Si, M.L.1
Zhu, S.2
Wu, H.3
-
148
-
-
55549120234
-
MicroRNA miR-21 over-expression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis
-
Yan LX, Huang XF, Shao Q, et al: MicroRNA miR-21 over-expression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14:2348-2360.
-
(2008)
RNA
, vol.14
, pp. 2348-2360
-
-
Yan, L.X.1
Huang, X.F.2
Shao, Q.3
-
149
-
-
74249112787
-
Therapeutic silencing of micro-RNA-122 in primates with chronic hepatitis C virus infection
-
Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al: Therapeutic silencing of micro-RNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327:198-201.
-
(2010)
Science
, vol.327
, pp. 198-201
-
-
Lanford, R.E.1
Hildebrandt-Eriksen, E.S.2
Petri, A.3
|